References
- Biason P, Hattinger CM, Innocenti F, et al (2012). Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy. Pharmacogenomics J, 12, 476-83. https://doi.org/10.1038/tpj.2011.33
- Caronia D, Patino-Garcia A, Milne RL, et al (2009). Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J, 9, 347-353. https://doi.org/10.1038/tpj.2009.19
- Dogan M, Karabulut HG, Tukun A, et al (2012). Relationship between antimetabolite toxicity and pharmacogenetics in Turkish cancer patients. Asian Pac J Cancer Prev, 13, 1553-6. https://doi.org/10.7314/APJCP.2012.13.4.1553
- Friedberg EC (2003) DNA damage and repair. Nature, 421, 436-40. https://doi.org/10.1038/nature01408
- Giachino DF, Ghio P, Regazzoni S, et al (2007). Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res, 13, 2876-81. https://doi.org/10.1158/1078-0432.CCR-06-2543
- Graf N, Ang WH, Zhu G, et al (2011). Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity. Chembiochem, 12, 1115-23. https://doi.org/10.1002/cbic.201000724
- Hatfield MD, Reis AM, Obeso D, et al (2006). Identification of MMS19 domains with distinct functions in NER and transcription. DNA Repai), 5, 914-24. https://doi.org/10.1016/j.dnarep.2006.05.007
- He C, Duan Z, Li P, et al (2013). Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer. Anticancer Drugs, 24, 300-305. https://doi.org/10.1097/CAD.0b013e32835bd6ce
- Italiano A, Laurand A, Laroche A, et al (2011). ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma. Cancer, 117, 3445-56. https://doi.org/10.1002/cncr.25925
- Koeppel F, Poindessous V, Lazar V, et al (2004). Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells. Clin Cancer Res, 10, 5604-13. https://doi.org/10.1158/1078-0432.CCR-04-0442
- Liu D, Wu HZ, Zhang YN, et al (2012). DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy. Mol Carcinog, 51, E83-93. https://doi.org/10.1002/mc.21862
- Longhi A, Errani C, De Paolis M, et al (2006). Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev, 32, 423-436. https://doi.org/10.1016/j.ctrv.2006.05.005
- Marina N, Gebhardt M, Teot L, et al (2004). Biology and therapeutic advances for pediatric osteosarcoma. Oncologist, 9, 422-41. https://doi.org/10.1634/theoncologist.9-4-422
- McWilliams RR, Bamlet WR, de Andrade M, et al (2009). Nucleotide excision repair pathway polymorphisms and pancreatic cancer risk: evidence for role of MMS19L. Cancer Epidemiol Biomarkers Prev, 18, 1295-302. https://doi.org/10.1158/1055-9965.EPI-08-1109
- Mudgett JS, MacInnes MA (1990) Isolation of the functional human excision repair gene ERCC5 by intercosmid recombination. Genomics, 8, 623-33. https://doi.org/10.1016/0888-7543(90)90248-S
- Rabik CA, Dolan ME (2007). Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev, 33, 9-23. https://doi.org/10.1016/j.ctrv.2006.09.006
- Sakano S, Hinoda Y, Sasaki M, et al (2010). Nucleotide excision repair gene polymorphisms may predict acute toxicity in patients treated with chemoradiotherapy for bladder cancer. Pharmacogenomics, 11, 1377-87. https://doi.org/10.2217/pgs.10.106
- Takahashi E, Shiomi N, Shiomi T (1992) Precise localization of the excision repair gene, ERCC5, to human chromosome 13q32.3- q33.1 by direct R-banding fluorescence in situ hybridization. Jpn J Cancer Res, 83, 1117-9. https://doi.org/10.1111/j.1349-7006.1992.tb02731.x
- Zhang L, Gao G, Li X, et al (2012). Association between single nucleotide polymorphisms (SNPs) and toxicity of advanced non-small-cell lung cancer patients treated with chemotherapy. PLoS One, 7, e48350. https://doi.org/10.1371/journal.pone.0048350
Cited by
- ERCC polymorphisms and prognosis of patients with osteosarcoma vol.35, pp.10, 2014, https://doi.org/10.1007/s13277-014-2322-1
- Methyl-methanesulfonate sensitivity 19 expression is associated with metastasis and chemoradiotherapy response in esophageal cancer vol.21, pp.14, 2015, https://doi.org/10.3748/wjg.v21.i14.4240
- Genetic variations in the PRKCG gene and osteosarcoma risk in a Chinese population: a case-control study vol.36, pp.7, 2015, https://doi.org/10.1007/s13277-015-3182-z
- Interleukin 10 gene −1082A/G polymorphism is associated with osteosarcoma risk and poor outcomes in the Chinese population vol.37, pp.4, 2016, https://doi.org/10.1007/s13277-015-4238-9
- The pharmacogenomics of osteosarcoma vol.17, pp.1, 2017, https://doi.org/10.1038/tpj.2016.45
- Association between the polymorphisms in XPG gene and gastric cancer susceptibility in Chinese populations vol.96, pp.42, 2017, https://doi.org/10.1097/MD.0000000000008213